Drug Profile
SYNSORB Cd
Alternative Names: SYNSORB CdLatest Information Update: 13 Dec 2001
Price :
$50
*
At a glance
- Originator SYNSORB Biotech
- Developer Omnicare; Paladin Labs; SYNSORB Biotech
- Class Antibacterials
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Clostridium difficile infections
Most Recent Events
- 13 Dec 2001 Discontinued-III for Clostridium difficile infections in Argentina (PO)
- 13 Dec 2001 Discontinued-III for Clostridium difficile infections in Canada (PO)
- 13 Dec 2001 Discontinued-III for Clostridium difficile infections in Mexico (PO)